Cytek Biosciences, Inc. CTKB Number of stock-based compensation plan

Other financials

Revenue$44.1M+6.5%

Gross profit$21.3M+5.4%

Operating income-$18.5M-23.3%

Net income-$18.9M-65.5%

EPS (diluted)-$0.15-66.7%

Cash & equivalents$31.8M-66.6%

Total debt$16.8M+40.9%

Total equity$327.6M-13.7%

Total assets$449.1M-6.9%

Operating cash flow-$2.7M-2,089%

CapEx$2.2M+155%

Free cash flow-$4.9M-403%

Market cap$577.27M+54.5%

Enterprise value$562.23M+93.7%

P/S2.8×+0.9×

Gross margin51.7%-3.2pp

Operating margin-21.5%—

Net margin-36.2%—

FCF margin-6.2%-15.1pp

Return on equity-20.9%—

Debt / equity0.1×0.0×

Current ratio4.7×-0.9×

Reported directly by Cytek Biosciences, Inc. in its filing.

Tagged under the XBRL concept ctkb:NumberOfStockBasedCompensationPlan.

The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Cytek Biosciences, Inc.'s number of stock-based compensation plan?: Cytek Biosciences, Inc. (CTKB) reported number of stock-based compensation plan of 3 in Q1 2026.